¼¼°èÀÇ ±âµµ È®º¸ ½Ã½ºÅÛ ½ÃÀå
Airway Clearance Systems
»óǰÄÚµå : 1544023
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 196 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,101,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,303,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ±âµµ È®º¸ ½Ã½ºÅÛ ½ÃÀåÀº 2030³â±îÁö 13¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â¿¡ 9¾ï 3,900¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ±âµµ È®º¸ ½Ã½ºÅÛ ½ÃÀåÀº 2030³â¿¡´Â 13¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ 2023-2030³â CAGRÀº 4.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ PEP(Positive Expiratory Pressure) ½Ã½ºÅÛÀº CAGR 4.9%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 3¾ï 9,620¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °íÁÖÆÄ È亮 Áøµ¿(HFCWO) ½Ã½ºÅÛ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 4.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 5,520¸¸ ´Þ·¯, Áß±¹Àº CAGR 4.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ±âµµ È®º¸ ½Ã½ºÅÛ ½ÃÀåÀº 2023³â¿¡ 2¾ï 5,520¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 2¾ï 380¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2023-2030³â CAGRÀº 4.4%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 4.3%¿Í 4.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ±âµµ È®º¸ ½Ã½ºÅÛ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

±âµµ È®º¸ ½Ã½ºÅÛÀÇ ±¸Á¶

±âµµ È®º¸ ½Ã½ºÅÛ(ACS)Àº ȯÀÚ°¡ ±âµµÀÇ Á¡¾×°ú ºÐºñ¹°À» Á¦°ÅÇϰí È£Èí ±â´ÉÀ» °³¼±ÇÏ¸ç °¨¿° À§ÇèÀ» ÁÙÀ̱â À§ÇØ °í¾ÈµÈ Áß¿äÇÑ ÀÇ·á±â±âÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ³¶Æ÷¼º ¼¶À¯Áõ, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), ±â°üÁöÈ®ÀåÁõ°ú °°Àº ¸¸¼º È£Èí±â ÁúȯÀ» ¾Î°í Àִ ȯÀڵ鿡°Ô ÇʼöÀûÀÔ´Ï´Ù. °íÁÖÆÄ È亮 Áøµ¿(HFCWO), È£±â ¾ç¾Ð(PEP), ±â°èÀû ±âº¹°ú °°Àº ´Ù¾çÇÑ ¸ÞÄ¿´ÏÁòÀÌ ÀÌ·¯ÇÑ Àåºñ¿¡ äÅõǾî Á¡¾×À» µ¿¿øÇÏ°í ¹èÃâÇÏ¿© Æó ±â´É°ú ȯÀÚÀÇ Æí¾ÈÇÔÀ» Çâ»ó½Ãŵ´Ï´Ù. Á¾Á¾ ACS´Â ÈíÀÔ ¿ä¹ý ¹× ¹°¸®Ä¡·á¿Í °°Àº ´Ù¸¥ Ä¡·á¿Í º´ÇàÇÏ¿© Á¾ÇÕÀûÀΠȣÈí±â Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù.

ACS¿¡¼­ ±â¼ú ¹ßÀüÀº ¾î¶² ¿ªÇÒÀ» Çϴ°¡?

±â¼úÀÇ ¹ßÀüÀº ACSÀÇ È¿°ú¿Í »ç¿ë ÆíÀǼºÀ» Å©°Ô Çâ»ó½ÃÄ×½À´Ï´Ù. ÃֽŠACS Àåºñ´Â ´õ ÀÛ°í ÈÞ´ë°¡ °£ÆíÇÏ¸ç »ç¿ëÇϱ⠽±±â ¶§¹®¿¡ ȯÀÚ´Â ÀÓ»ó ÇöÀå ´ë½Å Áý¿¡¼­ Ä¡·á¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù. °íÁÖÆÄ È亮 Áøµ¿ Á¶³¢´Â ȯÀÚÀÇ Çǵå¹é¿¡ µû¶ó Áøµ¿ÀÇ Á֯ļö¿Í °­µµ¸¦ Á¶Á¤ÇÏ´Â ½º¸¶Æ® ±â¼úÀÇ ÅëÇÕÀ¸·Î ´õ¿í È¿À²ÀûÀÔ´Ï´Ù. ÈÞ´ë¿ë PEP Àåºñ¿¡´Â ÇöÀç »ç¿ë·®À» ÃßÀûÇϰí ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ¸ðµÎ¿¡°Ô Çǵå¹éÀ» Á¦°øÇÏ´Â µðÁöÅÐ ¸ð´ÏÅͰ¡ ÀåÂøµÇ¾î ÀÖ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¹èÅ͸® ±â¼úÀÇ Çâ»óÀ¸·Î ÀÌ·¯ÇÑ Àåºñ´Â ´õ ¾ÈÁ¤ÀûÀÌ°í ¿À·¡ Áö¼ÓµÇ¾î Áö¼ÓÀûÀÎ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ¿ø°ÝÀÇ·á ±â´ÉÀ» ÅëÇÕÇÏ¿© ¿ø°Ý ¸ð´ÏÅ͸µ ¹× Ä¡·á ÇÁ·ÎÅäÄÝÀ» Á¶Á¤ÇÒ ¼ö ÀÖÀ¸¸ç, ¸¸¼º È£Èí±â ÁúȯÀÇ Àü¹ÝÀûÀÎ °ü¸®¸¦ °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ACSÀÇ ÀåÁ¡°ú °úÁ¦´Â?

±âµµ È®º¸ ½Ã½ºÅÛ »ç¿ë¿¡´Â ¸¹Àº ÀåÁ¡ÀÌ ÀÖÁö¸¸, µ¿½Ã¿¡ µµÀüµµ ÀÖ½À´Ï´Ù. ÀåÁ¡À¸·Î´Â ¸¸¼º È£Èí±â Áúȯ ȯÀÚÀÇ È£Èí±â °Ç°­°ú »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. Á¡¾×À» È¿°úÀûÀ¸·Î Á¦°ÅÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº Æó °¨¿°À» ¿¹¹æÇϰí ÀÔ¿øÀ» ÁÙÀ̸ç Àü¹ÝÀûÀÎ Æó ±â´ÉÀ» Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀçÅà ġ·á´Â ÆíÀǼºÀ» ³ôÀ̰í ÀÇ·á ½Ã¼³ÀÇ ºÎ´ãÀ» ÁÙÀ̸ç ȯÀÚÀÇ µ¶¸³¼ºÀ» ³ôÀÔ´Ï´Ù. ±×·¯³ª Ãʱâ Àåºñ ºñ¿ë°ú ÀûÀýÇÑ »ç¿ëÀ» º¸ÀåÇϱâ À§ÇØ Áö¼ÓÀûÀÎ Á¤ºñ ¹× ±³À°ÀÌ ÇÊ¿äÇÏ´Ù´Â Á¡ µîÀÌ ¹®Á¦Á¡À¸·Î ÁöÀûµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚ´Â Ä¡·á Áß ºÒÆíÇÔ°ú ÇǷθ¦ ´À³¥ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â Ä¡·á ÇÁ·ÎÅäÄÝ Áؼö¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ÃÖÀûÀÇ Ä¡·á °á°ú¸¦ ¾ò±â À§Çؼ­´Â ȯÀÚÀÇ µ¿±â¸¦ ºÎ¿©Çϰí Àåºñ¸¦ ¿Ã¹Ù¸£°Ô »ç¿ëÇÏ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ º¸Çè Àû¿ë ¹× »óȯ ¹®Á¦°¡ °æÁ¦Àû À庮À¸·Î ÀÛ¿ëÇÏ¿© ÀÌ·¯ÇÑ À¯ÀÍÇÑ ±â¼ú¿¡ ´ëÇÑ Á¢±ÙÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù.

ACS ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

±âµµ È®º¸ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡, ÀÇ·á °üÇàÀÇ ÁøÈ­¸¦ ¹Ý¿µÇÏ´Â ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â ³¶Æ÷¼º ¼¶À¯Áõ, COPD, ±â°üÁö È®ÀåÁõ°ú °°Àº ¸¸¼º È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡·Î È¿°úÀûÀÎ °ü¸® ¼Ö·ç¼ÇÀÌ ÇÊ¿äÇϸç, ACS ÀåºñÀÇ ±â´É¼º°ú »ç¿ë ÆíÀǼºÀ» Çâ»ó½ÃŰ´Â ±â¼ú ¹ßÀüÀº ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀçÅÃÄ¡·á µ¿Çâ¿Í ¿ø°ÝÀÇ·áÀÇ µµÀÔ Áõ°¡·Î ÀÎÇØ ÈÞ´ë°¡ °£ÆíÇÏ°í »ç¿ëÇϱ⠽¬¿î ±âµµ È®º¸ Àåºñ¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àû±ØÀûÀΠȣÈí °ü¸®ÀÇ ÀÌÁ¡¿¡ ´ëÇÑ È¯ÀÚ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀϺΠÁö¿ª¿¡¼­´Â ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú À¯¸®ÇÑ »óȯ Á¤Ã¥ÀÌ ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±â±âÀÇ È¿°ú¿Í ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀ̱â À§ÇÑ Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß ³ë·ÂÀº ½ÃÀå¿¡ »õ·Î¿î ±âȸ¸¦ âÃâÇϰí ÀÖÀ¸¸ç, ÇâÈÄ ¼ö³â°£ Áö¼ÓÀûÀÎ ¼ºÀåÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 46»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Airway Clearance Systems Market to Reach US$1.3 Billion by 2030

The global market for Airway Clearance Systems estimated at US$939.0 Million in the year 2023, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2023-2030. Positive Expiratory Pressure (PEP) System, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$396.2 Million by the end of the analysis period. Growth in the High Frequency Chest Wall Oscillation (HFCWO) System segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$255.2 Million While China is Forecast to Grow at 4.4% CAGR

The Airway Clearance Systems market in the U.S. is estimated at US$255.2 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$203.8 Million by the year 2030 trailing a CAGR of 4.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Airway Clearance Systems Market - Key Trends and Drivers Summarized

How Do Airway Clearance Systems Work?

Airway Clearance Systems (ACS) are essential medical devices designed to assist patients in clearing mucus and secretions from their airways, thereby enhancing respiratory function and decreasing the risk of infections. These systems are vital for individuals suffering from chronic respiratory conditions like cystic fibrosis, chronic obstructive pulmonary disease (COPD), and bronchiectasis. Various mechanisms such as high-frequency chest wall oscillation (HFCWO), positive expiratory pressure (PEP), and mechanical insufflation-exsufflation are employed by these devices to mobilize and expel mucus, improving lung function and patient comfort. Often, ACS are used alongside other treatments like inhalation therapy and physiotherapy to provide comprehensive respiratory care.

What Role Do Technological Advancements Play in ACS?

Technological advancements have greatly enhanced the effectiveness and usability of Airway Clearance Systems. Modern ACS devices are more compact, portable, and user-friendly, enabling patients to conduct treatments at home instead of in a clinical setting. High-frequency chest wall oscillation vests have become more efficient with the integration of smart technologies that adapt the frequency and intensity of oscillations based on patient feedback. Portable PEP devices now frequently feature digital monitors that track usage and provide feedback to both patients and healthcare providers. Improvements in battery technology have made these devices more reliable and longer-lasting, ensuring continuous access to treatments. Furthermore, the incorporation of telemedicine capabilities allows for remote monitoring and adjustment of treatment protocols, enhancing the overall management of chronic respiratory conditions.

What Are the Advantages and Challenges of ACS?

The use of Airway Clearance Systems offers numerous advantages but also presents certain challenges. Benefits include improved respiratory health and quality of life for patients with chronic respiratory conditions. By effectively clearing mucus, these systems help prevent lung infections, reduce hospitalizations, and enhance overall lung function. Home-based treatments add convenience, reducing the burden on healthcare facilities and granting patients greater independence. However, challenges include the initial cost of the devices and the need for ongoing maintenance and training to ensure proper usage. Patients may also experience discomfort or fatigue during treatments, which can impact adherence to therapy protocols. Ensuring patient motivation and correct use of the devices is crucial for optimal outcomes. Additionally, insurance coverage and reimbursement issues can pose financial barriers, limiting access to these beneficial technologies.

What Factors Are Driving Growth in the ACS Market?

The growth in the Airway Clearance Systems market is driven by several factors, reflecting advancements in technology, increasing prevalence of respiratory diseases, and evolving healthcare practices. One of the primary drivers is the rising incidence of chronic respiratory conditions such as cystic fibrosis, COPD, and bronchiectasis, necessitating effective management solutions. Technological advancements that enhance the functionality and ease of use of ACS devices significantly contribute to market growth. The trend towards home-based healthcare and the increasing adoption of telemedicine also drive the demand for portable and user-friendly airway clearance devices. Furthermore, growing awareness among patients and healthcare providers about the benefits of proactive respiratory care spurs the adoption of these systems. Regulatory approvals and favorable reimbursement policies in some regions further support market expansion. Additionally, ongoing research and development efforts aimed at improving device efficacy and patient compliance continue to generate new opportunities in the market, ensuring sustained growth in the coming years.

Select Competitors (Total 46 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â